The abstract is read at the publisher; the summary is JClub's.
In HER2-positive unresectable/metastatic breast cancer patients in China previously treated with trastuzumab and a taxane, trastuzumab botidotin improved PFS to 11.1 vs 4.4 months (HR 0.39).
- Why it matters: The trial addresses the need for safer, more effective HER2-directed options after prior trastuzumab and taxane therapy, where outcomes remain limited.
- What they did: In a phase III, open-label randomized study at 57 centers (NCT06968585), 365 adults were assigned 1:1 to trastuzumab botidotin or trastuzumab emtansine, with PFS assessed by blinded independent central review.
- The result: Final PFS analysis showed longer progression-free survival with trastuzumab botidotin (nominal P < .0001) and a higher objective response rate (76.9% vs 53.0%), alongside an ocular-heavy but largely recoverable toxicity pattern.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.